Northwestern Medicine scientists have discovered that an FDA-approved compound promotes neuroprotective effects in experimental models of Parkinson’s disease. The compound, N-acetyl-L-leucine (NALL), simultaneously targets multiple molecular pathways in dopaminergic neurons impacted by Parkinson’s disease, underscoring NALL’s potential therapeutic benefit in treating the disease in humans, according to the authors of the study published in the Journal of Clinical Investigation.
This article was originally published on MedicalXpress.com
